Roche Holding AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
TORPEDO Study: A Study on Rapid Effect of Tocilizumab in Patients With Rheumatoid Arthritis With an Inadequate Response to Disease-Modifying Antirheumatic Drugs (DMARDs) or Anti-TNF
Phase 3
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- Drug: tocilizumab [RoActemra/Actemra]Drug: placebo
- First Posted Date
- 2009-09-15
- Last Posted Date
- 2014-09-22
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 103
- Registration Number
- NCT00977106
A Study of Whole Brain Radiation Therapy and Capecitabine in Breast Cancer Participants With Newly Diagnosed Brain Metastasis
Phase 2
Terminated
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2009-09-15
- Last Posted Date
- 2016-11-15
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 24
- Registration Number
- NCT00977379
A Study of RO5036505 in Patients With Moderate to Severe Asthma
Phase 2
Withdrawn
- Conditions
- Asthma
- Interventions
- Drug: RO5036505Drug: placebo
- First Posted Date
- 2009-08-28
- Last Posted Date
- 2016-08-24
- Lead Sponsor
- Hoffmann-La Roche
- Registration Number
- NCT00967590
A Study of Avastin (Bevacizumab) and Irinotecan Versus Temozolomide Radiochemistry in Patients With Glioblastoma
Phase 2
Completed
- Conditions
- Glioblastoma Multiforme
- Interventions
- First Posted Date
- 2009-08-27
- Last Posted Date
- 2015-11-20
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 182
- Registration Number
- NCT00967330
A Study of Herceptin (Trastuzumab) in Combination With Avastin (Bevacizumab) and Sequential Xeloda (Capecitabine) or Docetaxel in Patients With HER2-Positive Locally Recurrent or Metastatic Breast Cancer
Phase 2
Withdrawn
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2009-08-25
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Registration Number
- NCT00964704
A Study of Subcutaneously Administered Tocilizumab in Patients With Rheumatoid Arthritis
Phase 1
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2009-08-25
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 29
- Registration Number
- NCT00965653
A Study of RO5190591 (Danoprevir) in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 Virus Infection
Phase 2
Completed
- Conditions
- Hepatitis C, Chronic
- Interventions
- First Posted Date
- 2009-08-24
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 229
- Registration Number
- NCT00963885
A Study of Early Immunologic Response in Asian Patients With Chronic Hepatitis B, Treated With Pegasys (Peginterferon Alfa-2a (40KD)), Nucleoside Analogues, or Both
Phase 1
Completed
- Conditions
- Hepatitis B, Chronic
- Interventions
- Drug: tenofovirDrug: peginterferon alfa-2a [Pegasys]
- First Posted Date
- 2009-08-20
- Last Posted Date
- 2016-02-08
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 30
- Registration Number
- NCT00962871
A Study of Pegasys Monotherapy in Patients With Chronic Hepatitis B Who Have Participated in Previous Studies
Phase 1
Completed
- Conditions
- Hepatitis B, Chronic
- Interventions
- Drug: peginterferon alfa-2a [Pegasys]
- First Posted Date
- 2009-08-20
- Last Posted Date
- 2014-04-08
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 29
- Registration Number
- NCT00962975
A Study of RO5095932 in Patients With Type 2 Diabetes Mellitus
Phase 1
Completed
- Conditions
- Diabetes Mellitus Type 2
- Interventions
- First Posted Date
- 2009-08-19
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 122
- Registration Number
- NCT00961909
© Copyright 2025. All Rights Reserved by MedPath